Sandip Kapadia has over 20 years of experience in building and leading finance and administration teams at life sciences companies both in Europe and in the United States. Mr. Kapadia has held numerous finance leadership positions over 19 years at Novartis and Novartis affiliates in the United States, Switzerland, the Netherlands, and the United Kingdom, including CFO of North America at Novartis’s generic division, Sandoz. He has been a director of Therachon AG since January 2019 and has served on the board of directors for Passage Bio since January 2020. Currently, Mr. Kapadia serves as CFO of Intercept Pharmaceuticals. Mr. Kapadia earned his bachelor’s degree in business administration and accounting from Montclair State University, an MBA from Rutgers Graduate School of Management, and is a certified public accountant.